Loading...
NPI 1508268731 · Gretna, LA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Medcomp Gx, LLC is a clinical medical laboratory provider located in Gretna, Louisiana. This profile covers 6 Medicare and 3 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Medcomp Gx, LLC |
| Address | 1799 Stumpf Blvd. |
| City | Gretna |
| State | LA |
| ZIP | 70056 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | September 18, 2014 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $7.8M |
| Medicaid | $13.7K |
MEDCOMP GX, LLC is overwhelmingly Medicare-revenue dominant: the provider reports $7.8M in total Medicare revenue versus $13.7K in total Medicaid revenue, making Medicare the primary payer by several orders of magnitude and effectively a single‑payer driver of overall revenue. This imbalance means analyses of business scale and risk should focus on Medicare activity.
Revenue concentration on Medicare is extreme: the precomputed top 3 Medicare codes account for 99.4% of the provider's Medicare revenue, with K1034 alone representing $7.8M (98.9% of Medicare revenue). That level of concentration indicates the organization’s Medicare business is driven almost entirely by one service line.
On Medicaid the concentration is likewise total: the precomputed top 3 Medicaid codes account for 100.0% of Medicaid revenue, and K1034 comprises 96.4% of the provider’s Medicaid revenue ($13.9K from 4.6K claims at $3 avg paid/claim). Despite the high in‑state rank on this code, Medicaid contributes only a small absolute dollar amount compared with Medicare.
K1034 is the dominant operational activity across both payers: for Medicare the provider billed 652K claims for K1034 at $12 avg paid/claim and $7.8M revenue, ranking #62 of 30143 providers nationally (100th percentile; extreme outlier). For Medicaid the provider billed 4.6K K1034 claims producing $13.9K and ranks #1 of 102 in‑state (100th percentile; extreme outlier). These statistics characterize the provider as a national/state outlier specifically for nonprescription self‑administered COVID‑19 tests.
Competitive standing on non‑COVID services is modest: molecular and genetic testing CPT/HCPCS such as 81307, 81201, 81317, 81298, and 81295 appear at low claim counts (roughly 26–30 claims each) and small revenue contributions (each in the ~$10.8K–$19.9K range), with national rank percentiles in the teens and twenties. This pattern indicates MEDCOMP GX maintains some molecular pathology capability but is not a major competitor in genetic testing volumes or revenue.
Payer reimbursement and volume patterns for the core code diverge: K1034 shows a large Medicare volume (652K claims at $12 avg paid/claim) versus a much smaller Medicaid volume (4.6K claims at $3 avg paid/claim), reflecting both payer mix and markedly different per‑claim payments for the same service. Analysts should treat reimbursement rates and claim volumes separately when modeling cash flow or utilization for this code.
The provider’s service mix implies a business model centered on high‑volume, low‑unit‑price diagnostic test provisioning (K1034) with a limited supplemental molecular pathology practice. The heavy skew toward a single low‑margin, high‑volume code suggests operational processes and distribution are optimized for mass testing rather than specialized diagnostic services.
MEDCOMP GX, LLC has an established Medicare enrollment history (NPI enumerated 2014-09-18, ~12 years ago), which indicates a sustained presence in the program; combined with the extreme concentration on K1034, this tenure suggests the organization shifted or scaled operations to exploit demand for nonprescription self‑administered COVID‑19 testing over recent policy and market cycles.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
6 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 652,030 | $10 | $7.8M |
| 81307 | The lab analyst performs the technical lab test on a specimen such as blood, to analyze the entire gene sequence for the partner and localizer of BRCA2 (PALB2) gene. | 30 | $660 | $19.9K |
| 81201 | The lab analyst performs the technical lab test to analyze the entire gene sequence for adenomatous polyposis coli, also known as APC. | 30 | $760 | $19.9K |
| 81317 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the postmeiotic segregation increased 2 [S. cerevisiae], or PMS2 gene. | 30 | $660 | $18.6K |
| 81298 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutS homolog 6 [E. coli], or MSH6 gene. | 30 | $630 | $18.2K |
| 81295 | The lab analyst performs the technical lab test to analyze the entire gene sequence for the mutS homolog 2, or MSH2 gene, also known as the colon cancer or nonpolyposis type 1 gene. | 30 | $370 | $10.8K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 6 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
3 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 4,620 | $1 | $13.9K |
| 81408 | The lab analyst performs the technical lab test to complete one of the specific genetic analyses listed in this Tier 2, Level 9 molecular pathology code. | 10 | $30 | $410 |
| 81406 | The lab analyst performs the technical lab test to complete one of the specific genetic analyses listed in this Tier 2, Level 7 molecular pathology code. | 10 | $10 | $110 |
How this provider's Medicaid billing volume and revenue compare to other Louisiana providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Louisiana median
3 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 81408 | The lab analyst performs the technical lab test to complete one of the specific genetic analyses listed in this Tier 2, Level 9 molecular pathology code. | 8 | 10 | 20 | $440 | $73.3K |
| 81406 | The lab analyst performs the technical lab test to complete one of the specific genetic analyses listed in this Tier 2, Level 7 molecular pathology code. | 7 | 10 | 20 | $100 | $22.8K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1 | 100 | 40 | $1 | $150 |
Other providers in the same ZIP code as Medcomp Gx, LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.